JP2002532393A - エキソ−ｒ−メカミラミン製剤および治療におけるその使用 - Google Patents

エキソ−ｒ−メカミラミン製剤および治療におけるその使用

Info

Publication number
JP2002532393A
JP2002532393A JP2000587609A JP2000587609A JP2002532393A JP 2002532393 A JP2002532393 A JP 2002532393A JP 2000587609 A JP2000587609 A JP 2000587609A JP 2000587609 A JP2000587609 A JP 2000587609A JP 2002532393 A JP2002532393 A JP 2002532393A
Authority
JP
Japan
Prior art keywords
mecamylamine
exo
effective amount
therapeutically effective
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000587609A
Other languages
English (en)
Japanese (ja)
Inventor
シャイトル，ダグラス
サンバーグ，ポール
ニューマン，メアリー
シルヴァー，アーチー
Original Assignee
ユニヴァーシティー オブ サウス フロリダ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オブ サウス フロリダ filed Critical ユニヴァーシティー オブ サウス フロリダ
Publication of JP2002532393A publication Critical patent/JP2002532393A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2000587609A 1998-12-16 1999-12-16 エキソ−ｒ−メカミラミン製剤および治療におけるその使用 Withdrawn JP2002532393A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11253498P 1998-12-16 1998-12-16
US60/112,534 1998-12-16
PCT/US1999/030137 WO2000035280A1 (en) 1998-12-16 1999-12-16 Exo-r-mecamylamine formulation and use in treatment

Publications (1)

Publication Number Publication Date
JP2002532393A true JP2002532393A (ja) 2002-10-02

Family

ID=22344414

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000587609A Withdrawn JP2002532393A (ja) 1998-12-16 1999-12-16 エキソ−ｒ−メカミラミン製剤および治療におけるその使用
JP2000587608A Pending JP2002532392A (ja) 1998-12-16 1999-12-16 エキソ−ｓ−メカミラミン製剤および治療におけるその使用
JP2011055716A Withdrawn JP2011126909A (ja) 1998-12-16 2011-03-14 エキソ−ｓ−メカミラミン製剤および治療におけるその使用
JP2013258032A Pending JP2014051528A (ja) 1998-12-16 2013-12-13 エキソ−ｓ−メカミラミン製剤および治療におけるその使用
JP2016011658A Pending JP2016065108A (ja) 1998-12-16 2016-01-25 エキソ−ｓ−メカミラミン製剤および治療におけるその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2000587608A Pending JP2002532392A (ja) 1998-12-16 1999-12-16 エキソ−ｓ−メカミラミン製剤および治療におけるその使用
JP2011055716A Withdrawn JP2011126909A (ja) 1998-12-16 2011-03-14 エキソ−ｓ−メカミラミン製剤および治療におけるその使用
JP2013258032A Pending JP2014051528A (ja) 1998-12-16 2013-12-13 エキソ−ｓ−メカミラミン製剤および治療におけるその使用
JP2016011658A Pending JP2016065108A (ja) 1998-12-16 2016-01-25 エキソ−ｓ−メカミラミン製剤および治療におけるその使用

Country Status (12)

Country Link
US (1) US20020016370A1 (enExample)
EP (3) EP1139743B1 (enExample)
JP (5) JP2002532393A (enExample)
AT (2) ATE320711T1 (enExample)
AU (2) AU2368200A (enExample)
CA (2) CA2393437C (enExample)
CY (1) CY1108577T1 (enExample)
DE (2) DE69939498D1 (enExample)
DK (2) DK1139743T3 (enExample)
ES (2) ES2313187T3 (enExample)
PT (2) PT1139743E (enExample)
WO (2) WO2000035280A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520379A (ja) * 2003-03-14 2006-09-07 エイジーアイ・セラピューティクス・リミテッド Ｎ−２，３，３−テトラメチルビシクロ［２．２．１］ヘプタン−２−アミンによる腸状態の治療
JP2013528178A (ja) * 2010-05-27 2013-07-08 ターガセプト，インコーポレイテッド ニコチン性受容体非競合的アンタゴニスト

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US7045534B2 (en) 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
EP1578422B1 (en) 2002-12-20 2007-04-11 NicoNovum AB A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
US20070224284A1 (en) * 2004-03-12 2007-09-27 John Devane Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
JP2009519962A (ja) * 2005-12-19 2009-05-21 コメンティス，インコーポレーテッド 眼投与用局所メカミルアミン製剤およびその使用
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
JP2010505960A (ja) * 2006-10-09 2010-02-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ニコチン禁断症状および／またはタバコ使用の軽減用組成物
US20080243005A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242952A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liablity Corporation Of The State Of Delaware Effective response protocols for health monitoring or the like
US20080319276A1 (en) * 2007-03-30 2008-12-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242947A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Configuring software for effective health monitoring or the like
US20080242948A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective low-profile health monitoring or the like
US20090018407A1 (en) * 2007-03-30 2009-01-15 Searete Llc, A Limited Corporation Of The State Of Delaware Computational user-health testing
US20090005653A1 (en) * 2007-03-30 2009-01-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242949A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20090119154A1 (en) * 2007-11-07 2009-05-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content
US20090005654A1 (en) * 2007-03-30 2009-01-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242951A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective low-profile health monitoring or the like
EP1977746B8 (en) * 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
WO2009143403A1 (en) * 2008-05-23 2009-11-26 Targacept, Inc. Combination therapy for the management hypertension
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
CA2764927A1 (en) * 2009-07-14 2011-01-20 Targacept, Inc. Exo-s-mecamylamine method, use, and compound for treatment
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
AT510837B1 (de) 2011-07-27 2012-07-15 Helmut Dr Buchberger Inhalatorkomponente
CA2824970C (en) 2011-02-11 2016-05-03 Batmark Limited Inhaler component
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
KR102671442B1 (ko) 2011-09-06 2024-05-30 니코벤처스 트레이딩 리미티드 가열식 끽연 가능 물질
MY164560A (en) 2011-09-06 2018-01-15 British American Tobacco Investments Ltd Heating Smokeable Material
AT511344B1 (de) 2011-10-21 2012-11-15 Helmut Dr Buchberger Inhalatorkomponente
US8901177B2 (en) * 2012-03-23 2014-12-02 Targacept, Inc. Method of treating bladder disorders
GB201207039D0 (en) 2012-04-23 2012-06-06 British American Tobacco Co Heating smokeable material
GB2504076A (en) 2012-07-16 2014-01-22 Nicoventures Holdings Ltd Electronic smoking device
GB2504075A (en) 2012-07-16 2014-01-22 Nicoventures Holdings Ltd Electronic smoking device
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
GB2513639A (en) 2013-05-02 2014-11-05 Nicoventures Holdings Ltd Electronic cigarette
GB2513637A (en) 2013-05-02 2014-11-05 Nicoventures Holdings Ltd Electronic cigarette
GB2514893B (en) 2013-06-04 2017-12-06 Nicoventures Holdings Ltd Container
GB201407426D0 (en) 2014-04-28 2014-06-11 Batmark Ltd Aerosol forming component
GB2528673B (en) 2014-07-25 2020-07-01 Nicoventures Holdings Ltd Aerosol provision system
ES2886106T3 (es) * 2014-08-22 2021-12-16 Atacama Therapeutics Inc Dexmecamilamina para su uso en el tratamiento de la hiperhidrosis
GB2533135B (en) 2014-12-11 2020-11-11 Nicoventures Holdings Ltd Aerosol provision systems
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
GB201505597D0 (en) 2015-03-31 2015-05-13 British American Tobacco Co Article for use with apparatus for heating smokable material
GB201505595D0 (en) 2015-03-31 2015-05-13 British American Tobacco Co Cartridge for use with apparatus for heating smokeable material
GB201511361D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic vapour provision system
GB201511349D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic aerosol provision systems
US20170055584A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Article for use with apparatus for heating smokable material
US11924930B2 (en) 2015-08-31 2024-03-05 Nicoventures Trading Limited Article for use with apparatus for heating smokable material
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
US20170119046A1 (en) 2015-10-30 2017-05-04 British American Tobacco (Investments) Limited Apparatus for Heating Smokable Material
US11744964B2 (en) 2016-04-27 2023-09-05 Nicoventures Trading Limited Electronic aerosol provision system and vaporizer therefor
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
GB202203728D0 (en) * 2022-03-17 2022-05-04 Univ Oxford Innovation Ltd Treatments and methods for increasing dopamine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039801A (en) * 1985-12-20 1991-08-13 The United States Of America As Represented By The Department Of Health & Human Services Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines
US4749686A (en) * 1986-12-04 1988-06-07 New York Medical College Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases
EP0302595B1 (en) * 1987-07-07 1994-02-02 Beecham Group Plc Pinacidil for treatment of pulmonary hypertension or right heart failure
US5691365A (en) * 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520379A (ja) * 2003-03-14 2006-09-07 エイジーアイ・セラピューティクス・リミテッド Ｎ−２，３，３−テトラメチルビシクロ［２．２．１］ヘプタン−２−アミンによる腸状態の治療
JP2013528178A (ja) * 2010-05-27 2013-07-08 ターガセプト，インコーポレイテッド ニコチン性受容体非競合的アンタゴニスト

Also Published As

Publication number Publication date
PT1139743E (pt) 2006-06-30
EP1139744A4 (en) 2003-01-02
JP2016065108A (ja) 2016-04-28
CA2393437A1 (en) 2000-06-22
DE69930552D1 (de) 2006-05-11
US20020016370A1 (en) 2002-02-07
EP1139743A4 (en) 2003-01-02
EP1634498A3 (en) 2006-03-29
ATE406797T1 (de) 2008-09-15
DK1139743T3 (da) 2006-07-31
EP1634498A2 (en) 2006-03-15
JP2011126909A (ja) 2011-06-30
ES2313187T3 (es) 2009-03-01
DE69930552T2 (de) 2006-11-30
DE69939498D1 (de) 2008-10-16
ES2260959T3 (es) 2006-11-01
CA2393437C (en) 2009-12-15
JP2014051528A (ja) 2014-03-20
WO2000035280A1 (en) 2000-06-22
PT1634498E (pt) 2008-10-28
AU2368600A (en) 2000-07-03
EP1139743B1 (en) 2006-03-22
EP1634498B1 (en) 2008-09-03
JP2002532392A (ja) 2002-10-02
EP1139744A1 (en) 2001-10-10
CY1108577T1 (el) 2014-04-09
WO2000035279A1 (en) 2000-06-22
EP1139743A1 (en) 2001-10-10
AU2368200A (en) 2000-07-03
CA2393442A1 (en) 2000-06-22
DK1634498T3 (da) 2008-12-15
ATE320711T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
JP2002532392A (ja) エキソ−ｓ−メカミラミン製剤および治療におけるその使用
AU2021382158B2 (en) Mdma prodrugs to assist psychotherapy
US10188613B2 (en) Exo-S-mecamylamine formulation and use in treatment
JP5698282B2 (ja) 痛みの治療のための混合されたＯＲＬ１／μ−アゴニスト
US10952976B2 (en) Compositions and methods for treating respiratory depression with fenfluramine
US20230233688A1 (en) Mdma prodrugs to assist psychotherapy
JP2009517393A (ja) 不安症の治療方法
JP4640888B2 (ja) 神経精神性疾患用ニコチンアンタゴニスト
US20030064988A1 (en) Pharmaceutically active morpholinol
WO1999007356A1 (en) Nicotine antagonists for neuropsychiatric disorders
Shytle et al. Exo-S-mecamylamine formulation and use in treatment
JP2010159285A6 (ja) 神経精神性疾患用ニコチンアンタゴニスト
JP2010159285A (ja) 神経精神性疾患用ニコチンアンタゴニスト
Engel Cocaine: A Historical and Modern Perspective

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20070306